Managers / Q2 2020 · view latest →
Redwood Investments, LLC
CIK 0001384058 · 265 FRANKLIN STREET, SUITE 1603, BOSTON, MA, 02110 · 617-467-3000
Summary
Redwood Investments, LLC reported $1.1B in U.S.-listed holdings across 122 positions for Q2 2020.
Its largest position, FRPT, represents 2.4% of the portfolio.
Compared with Q1 2020, the fund opened 17 new positions and exited 8.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 92.0% · $1.0B
- ADR · 3.2% · $36M
- Other · 2.5% · $28M
- REIT · 2.3% · $26M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| TXRHTEXAS ROADHOUSE INC | NEW | +367.5K | 367.5K | +$19M | $19M |
| INOVINOVALON HLDGS INC | NEW | +999.2K | 999.2K | +$19M | $19M |
| PFGCPERFORMANCE FOOD GROUP CO | NEW | +582.6K | 582.6K | +$17M | $17M |
| CHRSCOHERUS BIOSCIENCES INC | NEW | +894.2K | 894.2K | +$16M | $16M |
| LGNDLIGAND PHARMACEUTICALS INC | NEW | +110.7K | 110.7K | +$12M | $12M |
| HALOHALOZYME THERAPEUTICS INC | NEW | +446.1K | 446.1K | +$12M | $12M |
| KORNIT DIGITAL LTD | NEW | +179.8K | 179.8K | +$10M | $10M |
| EVEREVERQUOTE INC | NEW | +154.7K | 154.7K | +$9M | $9M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2020
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2025 | $267M | 96 | May 16, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $373M | 113 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $336M | 114 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $293M | 116 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $342M | 119 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $383M | 114 | Jan 19, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $739M | 112 | Oct 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $819M | 116 | Jul 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $783M | 116 | Apr 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $747M | 116 | Jan 20, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $744M | 116 | Oct 28, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $900M | 123 | Jul 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $1.1B | 127 | Apr 20, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $1.3B | 130 | Feb 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.2B | 129 | Oct 19, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.2B | 127 | Aug 2, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.1B | 123 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.2B | 124 | Feb 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $1.2B | 127 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $1.1B | 122 | Aug 3, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $847M | 113 | May 6, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.1B | 111 | Feb 4, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $1.3B | 126 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $1.4B | 136 | Jul 26, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.4B | 124 | May 7, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.